Novavax Inc (NVAX)

$8.69 -0.16 (-1.75%)
Market Cap 1.44B
Revenue (ttm) 682.16M
Net Income (ttm) -187.50M
EPS (ttm) N/A
PE Ratio 3.90
Forward PE N/A
Profit Margin -27.49%
Debt to Equity Ratio 0.00
Volume 3,326,000
Avg Vol 4,552,858
Day's Range N/A - N/A
Shares Out 162.50M
Stochastic %K 25%
Beta 2.37
Analysts Sell
Price Target $12.89

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 268 2000
Address:
700 Quince Orchard Road, Gaithersburg, United States
OneDollarBob
OneDollarBob Feb. 3 at 2:40 PM
$NVAX Pfizer having a rough morning.
0 · Reply
P38FTD
P38FTD Feb. 3 at 2:40 PM
$NVAX Look at the 5 year “performance” of PFE. They need some new leadership and new ideas- maybe a good start is our asset value partnership help IMO. Not investment advice, just say’n, ya know?
0 · Reply
ddirk
ddirk Feb. 3 at 2:39 PM
$NVAX shorts attacking early cause there scared
0 · Reply
LouAlwaysKnew
LouAlwaysKnew Feb. 3 at 2:38 PM
$NVAX @BTC321 JPMorgan involved with gates and epstein. The same ppl shorting our stock but coincidentally buying our debt
0 · Reply
BTC321
BTC321 Feb. 3 at 2:30 PM
$NVAX $PFE ty @ZacksResearch! Oh, can you finally manage to connect the dots as well? Or are you finally going to start putting two and two together? If you need more information or want to know what’s coming next, just ask the community on Stocktwits They’re usually three or four — sometimes even more — weeks ahead while others are just starting to figure things out.🤪
0 · Reply
Biotechlineup
Biotechlineup Feb. 3 at 2:23 PM
$NVAX The catalyst. Pfizer Earnings call at 10 am. Pfizer has already acknowledged that the Prevnar franchise has serious competition. Has already said it has plans for a 25 valent pneumococcal vaccine. If they mention matrix m in the same breath we have our catalyst.
1 · Reply
WPBFL
WPBFL Feb. 3 at 2:19 PM
$NVAX Pfizer’s $530 million agreement. NVAX potentially gets $140 million in development milestones and $360 million in sales milestones. It’s for up to two products so figure $70 million in development milestones per product. Figure it’s spread out half in 2026 and half in 2027. With $30 million upfront payment in 1Q that would be an additional $100 million in 2026 and $70 million in 2027. Of course the biggest potential revenue opportunity is the sales royalties and milestones.
0 · Reply
BTC321
BTC321 Feb. 3 at 2:17 PM
$NVAX https://x.com/LouieGiNYC/status/2018490593127616537?s=20
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 2:15 PM
🚀 $NVAX is up ~8.5% in the past two weeks — and the market is starting to connect the dots. Novavax just licensed its Matrix-M adjuvant to $PFE, locking in $30M upfront, up to $500M in milestones, and mid-single-digit royalties — with Pfizer handling development and commercialization. ⚡ Why this matters: • Validates Matrix-M as a platform, not a one-product asset • Expands a capital-light, royalty-driven revenue model • Adds to a growing list of partners (Pfizer, Sanofi, Oxford/Serum Institute) This isn’t a COVID trade anymore — it’s platform monetization gaining traction. 👉 Price target breakdown here 👇 https://www.zacks.com/stock/research/NVAX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-31601&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_31601
0 · Reply
DarvasBoxing
DarvasBoxing Feb. 3 at 2:06 PM
$NVAX thanks. This goes back a while. I’d nearly forgotten about this https://clinicaltrials.gov/study/NCT04645147
0 · Reply
Latest News on NVAX
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

Jan 30, 2026, 10:09 AM EST - 3 days ago

Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?

MRNA

Novavax Announces Entering into a License Agreement with Pfizer

Jan 20, 2026, 7:15 AM EST - 14 days ago

Novavax Announces Entering into a License Agreement with Pfizer

Novavax enters license agreement with Pfizer for vaccine development

Jan 20, 2026, 7:11 AM EST - 14 days ago

Novavax enters license agreement with Pfizer for vaccine development

PFE

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 10:15 PM EST - 19 days ago

Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 27 days ago

Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 2 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

BNTX MRNA PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 2 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

BNTX MRNA PFE

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

Dec 1, 2025, 9:59 AM EST - 2 months ago

Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals

MRNA

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:33 PM EST - 2 months ago

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Shah Capital pushes for Novavax sale, warns of proxy fight

Nov 12, 2025, 4:41 PM EST - 2 months ago

Shah Capital pushes for Novavax sale, warns of proxy fight

Novavax to Participate in Jefferies London Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 2 months ago

Novavax to Participate in Jefferies London Healthcare Conference

Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:26 PM EST - 3 months ago

Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 8:00 AM EST - 3 months ago

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Novavax raises annual revenue forecast on strength of vaccine deals

Nov 6, 2025, 7:58 AM EST - 3 months ago

Novavax raises annual revenue forecast on strength of vaccine deals

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Nov 4, 2025, 7:00 AM EST - 3 months ago

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 30, 2025, 8:00 AM EDT - 3 months ago

Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Oct 22, 2025, 7:00 AM EDT - 3 months ago

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Oct 14, 2025, 1:08 PM EDT - 3 months ago

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps

Oct 14, 2025, 6:09 AM EDT - 4 months ago

Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Oct 7, 2025, 7:00 AM EDT - 4 months ago

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

Novavax Announces Progress on Sanofi Agreement

Sep 30, 2025, 9:01 AM EDT - 4 months ago

Novavax Announces Progress on Sanofi Agreement

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 4 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

BNTX MRNA PFE

Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 2:10 PM EDT - 5 months ago

Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Sep 4, 2025, 8:00 AM EDT - 5 months ago

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

Novavax to Participate in the Cantor Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 5 months ago

Novavax to Participate in the Cantor Global Healthcare Conference

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Aug 27, 2025, 3:07 PM EDT - 5 months ago

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Novavax Announces Convertible Debt Refinancing

Aug 21, 2025, 7:43 AM EDT - 5 months ago

Novavax Announces Convertible Debt Refinancing

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:56 PM EDT - 6 months ago

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Novavax beats quarterly revenue estimates on milestone payment

Aug 6, 2025, 8:08 AM EDT - 6 months ago

Novavax beats quarterly revenue estimates on milestone payment

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 6, 2025, 8:00 AM EDT - 6 months ago

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 8:00 AM EDT - 6 months ago

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Jul 24, 2025, 11:02 AM EDT - 6 months ago

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Jul 24, 2025, 8:00 AM EDT - 6 months ago

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 11, 2025, 8:59 PM EDT - 8 months ago

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Jun 11, 2025, 7:11 AM EDT - 8 months ago

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Jun 11, 2025, 7:00 AM EDT - 8 months ago

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Vaccine actions and policy positions under US Health Secretary Kennedy

Jun 10, 2025, 10:45 AM EDT - 8 months ago

Vaccine actions and policy positions under US Health Secretary Kennedy

BNTX MRNA PFE

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Jun 10, 2025, 9:30 AM EDT - 8 months ago

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

BNTX MRNA PFE

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Jun 10, 2025, 8:18 AM EDT - 8 months ago

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

BNTX MRNA PFE SNY

Novavax to Participate in Upcoming Investor Conferences

May 29, 2025, 8:00 AM EDT - 8 months ago

Novavax to Participate in Upcoming Investor Conferences

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

May 21, 2025, 8:15 AM EDT - 9 months ago

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

May 20, 2025, 4:34 PM EDT - 9 months ago

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

May 19, 2025, 12:15 PM EDT - 9 months ago

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

AZO TSLA

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

May 19, 2025, 9:27 AM EDT - 9 months ago

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

May 19, 2025, 7:16 AM EDT - 9 months ago

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 19, 2025, 7:00 AM EDT - 9 months ago

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

FDA approves Novavax COVID vaccine with new conditions

May 17, 2025, 10:26 PM EDT - 9 months ago

FDA approves Novavax COVID vaccine with new conditions

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

May 14, 2025, 10:46 PM EDT - 9 months ago

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

May 12, 2025, 12:45 PM EDT - 9 months ago

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

May 8, 2025, 1:31 PM EDT - 9 months ago

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

OneDollarBob
OneDollarBob Feb. 3 at 2:40 PM
$NVAX Pfizer having a rough morning.
0 · Reply
P38FTD
P38FTD Feb. 3 at 2:40 PM
$NVAX Look at the 5 year “performance” of PFE. They need some new leadership and new ideas- maybe a good start is our asset value partnership help IMO. Not investment advice, just say’n, ya know?
0 · Reply
ddirk
ddirk Feb. 3 at 2:39 PM
$NVAX shorts attacking early cause there scared
0 · Reply
LouAlwaysKnew
LouAlwaysKnew Feb. 3 at 2:38 PM
$NVAX @BTC321 JPMorgan involved with gates and epstein. The same ppl shorting our stock but coincidentally buying our debt
0 · Reply
BTC321
BTC321 Feb. 3 at 2:30 PM
$NVAX $PFE ty @ZacksResearch! Oh, can you finally manage to connect the dots as well? Or are you finally going to start putting two and two together? If you need more information or want to know what’s coming next, just ask the community on Stocktwits They’re usually three or four — sometimes even more — weeks ahead while others are just starting to figure things out.🤪
0 · Reply
Biotechlineup
Biotechlineup Feb. 3 at 2:23 PM
$NVAX The catalyst. Pfizer Earnings call at 10 am. Pfizer has already acknowledged that the Prevnar franchise has serious competition. Has already said it has plans for a 25 valent pneumococcal vaccine. If they mention matrix m in the same breath we have our catalyst.
1 · Reply
WPBFL
WPBFL Feb. 3 at 2:19 PM
$NVAX Pfizer’s $530 million agreement. NVAX potentially gets $140 million in development milestones and $360 million in sales milestones. It’s for up to two products so figure $70 million in development milestones per product. Figure it’s spread out half in 2026 and half in 2027. With $30 million upfront payment in 1Q that would be an additional $100 million in 2026 and $70 million in 2027. Of course the biggest potential revenue opportunity is the sales royalties and milestones.
0 · Reply
BTC321
BTC321 Feb. 3 at 2:17 PM
$NVAX https://x.com/LouieGiNYC/status/2018490593127616537?s=20
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 2:15 PM
🚀 $NVAX is up ~8.5% in the past two weeks — and the market is starting to connect the dots. Novavax just licensed its Matrix-M adjuvant to $PFE, locking in $30M upfront, up to $500M in milestones, and mid-single-digit royalties — with Pfizer handling development and commercialization. ⚡ Why this matters: • Validates Matrix-M as a platform, not a one-product asset • Expands a capital-light, royalty-driven revenue model • Adds to a growing list of partners (Pfizer, Sanofi, Oxford/Serum Institute) This isn’t a COVID trade anymore — it’s platform monetization gaining traction. 👉 Price target breakdown here 👇 https://www.zacks.com/stock/research/NVAX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-31601&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_31601
0 · Reply
DarvasBoxing
DarvasBoxing Feb. 3 at 2:06 PM
$NVAX thanks. This goes back a while. I’d nearly forgotten about this https://clinicaltrials.gov/study/NCT04645147
0 · Reply
BTC321
BTC321 Feb. 3 at 1:59 PM
$NVAX that's what our partner does... https://finance.yahoo.com/news/press-release-sanofi-announces-signing-060000958.html
2 · Reply
P38FTD
P38FTD Feb. 3 at 1:46 PM
$NVAX The good, the bad and the ugly in reverse order. The ugly. Having to negotiate life sustaining business terms with enemies who are naturally inclined to prefer to conspire, weaken, plunder and seize instead. The bad. A management team negotiating terms for survival in this environment (“winning the hand) but seemingly unaware of the business cards they hold and how to play them. The good. The very likely undeniable reality that eventually the management team understands that they are holding a biotechnology royal straight flush and finally start to monetize it at the correct value successfully and consistently. The backdrop- our enemies and the enemies of our enemies must become our business partners (“friends”) if we are to survive. This is only my take and is not investment advice.
1 · Reply
DrFUShorts
DrFUShorts Feb. 3 at 1:45 PM
$NVAX Could provide $500M- 1B/year of continuos royalties to NVAX if materialized. https://www.persistencemarketresearch.com/market-research/shingles-vaccine-market.asp
0 · Reply
Paulchowda
Paulchowda Feb. 3 at 1:39 PM
$NVAX it might be a good day, we will have to wait, sitting down, minding my own business having coffee oh yeah, you bet
2 · Reply
Hoodoo_Voodoo
Hoodoo_Voodoo Feb. 3 at 1:23 PM
$NVAX I think we cross the 200MA today 🟢
1 · Reply
DifferentRadar
DifferentRadar Feb. 3 at 1:21 PM
$NVAX Insight on the M&A strategies of the biotech sector. Basically, there is a bias to make later stage deals, earlier stage deals that are AI driven, as well as an increase of interest in doing licensing deals vs. full buyouts. All of which are positive for Novavax. https://www.pharmavoice.com/news/investor-biotech-bets-late-early-stage-gap-jp-morgan/811157/
0 · Reply
stock_gan
stock_gan Feb. 3 at 1:19 PM
$NVAX ​Pfizer did not explicitly name the two disease fields today. However, they dropped a strong clue during the R&D segment: ​They mentioned a focus on "high-burden respiratory and shingles-related illnesses" where current immune responses could be "further optimized." This strongly signals that Shingles or RSV is the likely first field. If Shingles is confirmed in a future press release, it’s a "diamond" for Novavax because that is a multi-billion dollar market where Matrix-M’s high T-cell response is a massive advantage.
1 · Reply
DifferentRadar
DifferentRadar Feb. 3 at 1:15 PM
$NVAX More on the debate on removing mRNA vaccines between the FDA and ACIP. https://www.pharmexec.com/view/acip-member-claims-fda-commissioner-halting-decision-remove-covid-vaccines-from-market-report
2 · Reply
cayenne
cayenne Feb. 3 at 1:14 PM
$NVAX Morning Bulls!
1 · Reply
Superforce_57
Superforce_57 Feb. 3 at 1:13 PM
$NVAX Fire John "Happy Talk/Penny Stock" Jacobs
0 · Reply
wintogether
wintogether Feb. 3 at 12:59 PM
$NVAX no mention of novavax or matrix M on Pfizer's report. JJ unsatified.
0 · Reply
Chelsea100
Chelsea100 Feb. 3 at 12:48 PM
$NVAX SI should be over 42% Fully loaded against the share price. Management is doing absolutely nothing.
1 · Reply